The abstract is read at the publisher; the summary is JClub's.
PRGN-3008 CD19 CAR T cells engineered with mbIL-15 and PD-1-targeting microRNAs preserve polyfunctionality and sustained cytotoxicity across repeated tumor challenges.
- Why it matters: CAR T therapies face translational barriers including manufacturing complexity, safety concerns, and therapeutic durability driven by exhaustion during chronic antigen exposure.
- What they did: The team used decentralized overnight manufacturing without ex vivo expansion and a single nonviral transposon to encode CD19 CAR, mbIL-15, PD-1-targeting microRNAs, plus an inducible safety switch.
- The result: In xenograft models, overnight-manufactured PRGN-3008 achieved durable tumor clearance and prolonged tumor-free survival, and in humanized lupus models it maintained effector function and depleted autoreactive B cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.